Glycozide M 40mg/500mg Tablet SR is a combination oral hypoglycemic agent containing Gliclazide 40mg and Metformin 500mg in a sustained-release formulation, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels, while Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity. The sustained-release formulation ensures a gradual release of active ingredients, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. Glycozide M is prescribed as part of a comprehensive diabetes management plan including diet, exercise, and lifestyle modifications. It is particularly beneficial for patients inadequately controlled on monotherapy or those requiring dual therapy to achieve target glycemic levels. Caution is advised in patients with renal or hepatic impairment, cardiovascular conditions, or a history of lactic acidosis. Regular monitoring of blood glucose, renal function, and potential adverse effects such as hypoglycemia is essential during treatment. This combination therapy offers an effective approach to optimizing glycemic control and minimizing diabetes-related complications when used under medical supervision.

Dosage & How to Use